Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Acq. announced
Quarterly results
Appointed director
CC transcript

PLUS THERAPEUTICS, INC. (CYTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/21/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/14/2023 8-K Quarterly results
Docs: "Investor Contact"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
05/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements AUSTIN, Texas, May 16, 2023 - Plus Therapeutics, Inc. , a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that it has received notification from The Nasdaq Stock Market LLC that the staff has determined that for the last 10 consecutive business days, from May 1, 2023 to May 12, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Therefore, the Company has regained compliance with Listing Rule 5550. Accordingly, Nasdaq has advised that the matter is now closed. About Plus Therapeutics Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing t..."
04/28/2023 8-K Quarterly results
04/21/2023 8-K Quarterly results
04/20/2023 8-K Quarterly results
04/20/2023 10-Q Quarterly Report for the period ended March 31, 2023
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/07/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/24/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/23/2023 8-K Quarterly results
Docs: "Peter Vozzo ICR Westwicke 377-4767 [email protected] Terri Clevenger ICR Westwicke 856-4326 [email protected]"
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/15/2022 8-K Quarterly results
11/28/2022 8-K Quarterly results
10/20/2022 8-K Quarterly results
10/20/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/22/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "OWNERSHIP AND INTELLECTUAL PROPERTY PROTECTION",
"Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas"
09/09/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Distribution Agreement, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC",
"Opinion of Hogan Lovells LLP"
09/09/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/18/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/17/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/17/2022 8-K Other Events  Interactive Data
Docs: "FORM 8-K"
08/08/2022 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
08/08/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Purchase Agreement, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC",
"Registration Rights Agreement, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC"
07/21/2022 8-K Quarterly results
07/21/2022 10-Q Quarterly Report for the period ended June 30, 2022
05/27/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
04/21/2022 8-K Quarterly results
Docs: "Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186 RNL for leptomeningeal metastases"
04/21/2022 10-Q Quarterly Report for the period ended March 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy